SCHEMBL7024732

SCHEMBL7024732

C[C@H](Nc1nccc(-n2cnc3ccccc32)n1)c1cccc(C(=O)Nc2cccc3ccccc23)c1

nearest known ligand 0.62

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
LCK P06239 20/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7655090 0.89 LCK (0.70) LCK
SCHEMBL7021544 0.89 LCK (0.60) LCK
SCHEMBL7017569 0.86 LCK (0.63) LCK
SCHEMBL7027204 0.85 LCK (0.73) LCK
SCHEMBL7023423 0.85 LCK (0.70) LCK
SCHEMBL7018421 0.85 LCK (0.76) LCK
SCHEMBL7021478 0.85 LCK (0.66) LCK
SCHEMBL7020476 0.85 LCK (0.61) LCK
SCHEMBL7023318 0.84 LCK (0.74) LCK
SCHEMBL7019715 0.84 LCK (0.66) LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 EP disclosed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 US disclosed